TY - JOUR
AR - ORD-2019-1-105
TI - Current Approaches in Dental Alveolar Abscess in Sight of Bone Related Drugs
AU - Adel, M. Abdel-Hakem
AU - El-Shimaa M. N., Abdelhafez
AU - Salsabel, M. N. A. Ali
AU - Sara Mohamed, Naguib Abdelhafez
JO - Oral Rehabilitation and Dentistry
PY - 2019
DA - Mon 30, Dec 2019
SN - 2733-2543
DO - http://dx.doi.org/10.31487/j.ORD.2019.01.05
UR - https://www.sciencerepository.org/current-approaches-in-dental-alveolar-abscess_ORD-2019-1-105 
KW - Abscess, Osteoclast, osteoblast, bone resorption, drugs
AB - Dentoalveolar abscess, a localized accumulation of pus in the alveolar bone, can produce significant changes
in alveolar bone proper that may be resulted by dental caries, trauma or pulpitis causing alveolar bone
resorption or even loss. Unfortunately, it can extend vertically toward the apex of the tooth. Additionally,
a periapical abscess may form in the alveolar bone adjacent to the apex of the tooth. Interestingly, many
bacterial products can stimulate osteoclast formation and bone resorption of periapical tissues. This review
displayed drugs that can affect bone resorption that classified as (1) Osteoclast inhibitors such as:
bisphosphonates, gene therapeutic (Cathepsin K) estrogens, selective estrogen receptor modulators
(SERMs), calcitonin monoclonal antibodies such as denosumab and (2) Osteoclast activators such as DMPPYT, nuclear factor-Kappa B (RANK) signaling and adrenomedullin.